LY 288513

Key Product Details

Product Description

LY 288513 is a selective CCK₂ receptor antagonist (IC₅₀ values are 16 and > 30,000 nM for CCK₂ and CCK₁ respectively). Displays anxiolytic and antipsychotic properties in vivo.

Licensing Information

Sold with the permission of Eli Lilly and Company

Product Specifications for LY 288513

The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.

Solubility

Preparing Stock Solutions for LY 288513

The following data is based on the product molecular weight 436.30.

Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which all affect the solvent volumes required to prepare stock solutions.

Select a batch to recalculate based on the batch molecular weight:

3 2 1 Recalculate

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	2.29 mL	11.46 mL	22.92 mL
5 mM	0.46 mL	2.29 mL	4.58 mL
10 mM	0.23 mL	1.15 mL	2.29 mL
50 mM	0.05 mL	0.23 mL	0.46 mL

Calculators

Background References

References are publications that support the biological activity of the product. See our Citations tab to view 5 publications citing the usage of this product.

• Helton Central nervous system characterization of the new cholecystokininB antagonist LY288513. Pharmacol.Biochem.Behav. 1996 PMID: 8866946
• Rasmussen Electrophysiological effects of diphenylpyrazolidinone cholecystokinin-B and cholecystokinin-A antagonists on midbrain DA neurons. J.Pharmacol.Exp.Ther.
• Rasmussen CCK, schizophrenia, and anxiety. CCK-B antagonists inhibit the activity of brain DA neurons. Ann.N.Y.Acad.Sci. 1994 PMID: 8185172

Product Documents for LY 288513